Molecule intelOpportunity: ModerateEssential

Ramipril

38 brands · 19 companies · product forms

ATC: C09AA05

Opportunity snapshot

Launch attractiveness
45
Market saturation
52
Price room
100
Regulatory risk
0
38
brands
19
companies
Rs 536.29
median price
29
price points
7.15x
price spread
100
confidence %

Who competes here

Top companies by brand count — fragmented market (no dominant player) · leader share 18%

Price room

Across observed sources and strengths
CheapestRs 169.14
MedianRs 536.29
Most expensiveRs 1,209.6
Spread7.15×
Sources: DRAP-official, DVAGO, Servaid

max/min price ratio 7.15x across 29 trusted points (Rs 169.14-1209.6). NOTE: mixes strengths (graph prices carry no strength), so treat as indicative.

Brands & products on the market

Sample of 8 live products for Ramipril — each links to its own medicine page.

Why this score

Launch attractiveness

40% supply-gap(25) + 25% price-variation(100) + 20% low-competition(48) + 15% supply-disruption(0), damped by confidence(100). Higher = more attractive, less crowded opportunity.

Market saturation

19 canonical companies and 38 brands compete (saturation pegged at 30 companies / 150 brands).

Price room

max/min price ratio 7.15x across 29 trusted points (Rs 169.14-1209.6). NOTE: mixes strengths (graph prices carry no strength), so treat as indicative.

Regulatory risk

No DRAP alerts on this molecule's brands.

Confidence

Full coverage.

Packaged brief for this moderate opportunity?

Molecule page + company profiles + price-room analysis are the pilot package for pharma teams.

See packaged reports All 3868 molecules

Molecule intelligence as of 2026-07-30. Brand/company counts from DRAP registry and observed retail sources.

For medicine intelligence and professional reference only. Not medical advice.